CD8A and neoplasm: Given that luteolin increased the number of CD8+ T lymphocytes in the spleen, peripheral blood and tumour tissues of H22 tumour‐bearing mice, we hypothesize that luteolin can enhance the anti‐tumour effect of the PD‐1 inhibitor.